ACE and COVID-19: The prevalence of cardia-cerebrovascular diseases in patients with COVID-19 was much higher than that of general population, which may be explained by the long-term use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs), which upregulate ACE2, leading to an increase in contracting SARS-CoV-2 [60, 61].